Investor Relations

Website Notice Block

Corporate Profile

MediWound Ltd. (Nasdaq: MDWD) is the global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. The Company specializes in the development, production and commercialization of rapid and effective biologics that improve existing standards of care and patient experiences, while reducing costs and unnecessary surgeries.

Change
Volume
52 Week High
52 Week Low

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Events
Investor Presentation
Quarterly Results

Press Releases

MediWound Announces $25 Million Strategic Private Placement Financing

July 15, 2024

Mölnlycke Health Care, a global leader in innovative wound care solutions, leads the PIPE with a $15 million investment YAVNE, Israel, July 15, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the world leader in next-generation enzymatic therapeutics for tissue repair, today announced it

MediWound Reports First Quarter 2024 Financial Results and Provides Company Update

May 29, 2024

 NexoBrid ® interest surges; $5 million in Q1 2024 revenue, with $24 million forecast for the year Manufacturing facility on target for completion by mid-2024 EscharEx ® Phase III study to launch 2H 2024 Company set to join Russell 3000® Index Conference call today, May 29 at 8:30am Eastern Time

View All Press Releases  ///